Intensity Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lewis H. Bender
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 61 Wilton Road Westport CT United States of America 06880
- IPO Date
- Jun 30, 2023
- CIK
- 0001567264
- Website
- intensitytherapeutics.com
- Similar Companies
- Business
- Intensity Therapeutics, Inc. (Nasdaq: INTS) is a clinical-stage biotechnology company developing proprietary intratumoral immuno-oncology therapies to treat solid tumor cancers. The company offers a pipeline of product candidates including INT230-6, its lead therapy comprising doxorubicin, vincristine, and pemetrexed in a unique DOXILPEGE polymer; INT2104, a targeted therapy for triple-negative breast cancer; and INT2106 for pancreatic cancer, all delivered via proprietary DfuseX technology platform that enables direct tumor injection for enhanced immune response and reduced systemic toxicity. These therapies target difficult-to-treat solid tumors such as breast, pancreatic, sarcoma, and colorectal cancers; serve pharmaceutical partners and clinical trial patients; and operate primarily in the United States with headquarters in Weston, Massachusetts, founded in 2012. In recent developments, Intensity Therapeutics announced positive topline results from its INVINCIBLE-2 Phase 3 trial of INT230-6 in advanced soft tissue sarcoma in late 2024, demonstrating significant progression-free survival benefits. The company expanded its pipeline with the initiation of the INVINCIBLE-3 trial for presurgical breast cancer in early 2025 and secured a strategic collaboration with a major pharmaceutical partner for combination therapy development in Q3 2025. Additionally, Intensity completed a $50 million follow-on equity financing in September 2025 to support ongoing Phase 3 trials and manufacturing scale-up, marking no significant name changes or reorganizations within the last two years.
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Intensity Therapeutics Announces Reverse Stock Split
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
All You Need to Know About Intensity Therapeutics Inc. (INTS) Rating Upgrade to Buy
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Intensity Therapeutics, Inc. (INTS) Discusses eBioMedicine Paper Study Results and Underlying Technology Transcript
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock